478868-68-7

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 4-(2,4-dichlorophenyl)-2,4-dioxobutanoate is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential to exhibit anti-inflammatory and analgesic effects, which are crucial for the treatment of pain and inflammation.
Used in Organic Synthesis:
In the field of organic synthesis, ethyl 4-(2,4-dichlorophenyl)-2,4-dioxobutanoate serves as a versatile building block for the creation of complex organic molecules, contributing to the advancement of chemical research and the development of new materials.

InChI:InChI=1/C12H10Cl2O4/c1-2-18-12(17)11(16)6-10(15)8-4-3-7(13)5-9(8)14/h3-5H,2,6H2,1H3

Upstream product

• 1475-13-4 2,4-dichloro-α-methylbenzyl alcohol 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 95-92-1 oxalic acid diethyl ester 
• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 

Downstream Products

• 712348-40-8 C₁₀H₅Cl₂NO₃ 
• 135473-24-4 ethyl 5-(2,4-dichlorophenyl)-2-methyl-2H-pyrazole-3-carboxylate 
• 133113-04-9 5-(2,4-dichlorophenyl)-2-methyl-2H-pyrazole-3-carboxylic acid 
• 1256937-67-3 2-amino-3-cyano-7-dimethylamino-4-(5-(2,4-dichlorophenyl)isoxazol-3-yl)-4H-chromene 
• 925007-08-5 (5-(2,4-dichlorophenyl)isoxazol-3-yl)methanol 
• 159427-17-5 ethyl 5-(2,4-dichlorophenyl)isoxazole-3-carboxylate 
• 869496-67-3 5-(2,4-dichlorophenyl)isoxazole-3-carbaldehyde 

Relevant academic research and scientific papers

Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents

The complex pathophysiology of Alzheimer's disease (AD) has prompted researchers to develop multitarget-directed molecules to find an effective therapy against the disease. In this context, a novel series of N-(1-benzylpiperidin-4-yl)-5-arylisoxazole-3-ca

Green and efficient synthesis of new pyrido[2,3-d]pyrimidine derivatives using Pd/SBA-15 as a nanocatalyst

N-Fused heterocycles have received significant attention over the years as valuable compounds due to their biological and pharmaceutical activities. Heterogeneous catalysts such as periodic mesoporous materials have played an important role in the synthes

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Antibiotic resistance among clinically significant bacterial pathogens is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compounds B14 and B16 that possessed the isoxazol-5-yl group showed strong antibacterial activity against various testing strains, including methicillin-resistant Staphylococcus aureus and penicillin-resistant S. aureus. Further molecular biological studies and docking analyses proved that the compound functioned as an effective inhibitor to alter the dynamics of FtsZ self-polymerization via a stimulatory mechanism, which finally terminated the cell division and caused cell death. Taken together, these results could suggest a promising chemotype for development of new FtsZ-targeting bactericidal agent.

Simple and efficient syntheses of novel benzo[4,5]imidazo[1,2-a]pyridine derivatives

A novel series of benzo[4,5]imidazo[1,2-a]pyridine derivatives is synthesized through the reaction of 2-(1H-benzo[d]imidazol-2-yl)acetonitrile and different ethyl 2,4-dioxo-4-arylbutanoate derivatives in the presence of piperidine in refluxing EtOH. All the products are easily prepared within 25-45 min in good to excellent yields.

Facile, novel and efficient synthesis of new pyrazolo[3,4-b]pyridine products from condensation of pyrazole-5-amine derivatives and activated carbonyl groups

An efficient synthesis of novel ethyl-1,3,4-triphenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylate products has been achieved via condensation of pyrazole-5-amine derivatives and activated carbonyl groups, in refluxing acetic acid. This process has been found to be useful in the preparation of new N-fused heterocycle products in good to excellent yields.

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.

The synthesis of a series of 3-aryl pyrazolo[4,3-d]pyrimidines as potential corticotropin-releasing factor (CRF-1) antagonists is described. The effects of substitution on the aromatic ring, the amino group and the pyrazolo ring on CRF-1 receptor binding